S100A6 and pachyonychia congenita: In conclusion, this study proposed the shared gene signatures to illustrate the possible mechanism of PC and T2DM (Figure 10), revealed that the regulation of endodermal cell fate specification might be a common pathway, and identified S100A6 as an immune-related biomarker and potential therapeutic target for patients with PC and T2DM.